Founded in 2010, Internis is a UK speciality pharmaceutical company engaged in the development and commercialisation of highly effective and innovative medicines currently aimed at the treatment and prevention of a range of common bone disorders, such as osteoporosis and vitamin D3 deficiency.
Internis has grown rapidly in the past 4 years since commercialising their first product Accrete-D3. It is positioned now as one of the UK’s fastest growing pharmaceutical companies and is still expanding, by focusing on niche branded products where there is an unmet medical need.
Internis recognises the important work of the National Osteoporosis Society and is committed to supporting them through the Bone Health Partnership.
At Consilient Health we are passionate about developing and supplying prescription medicines that provide benefits to Patients and Prescribers and the NHS. This is achieved through building strong partnerships with our manufacturing, distribution and pharmacy partners. We offer one of the widest ranges of oral contraceptives in the UK, offering high quality products and significant savings for the NHS, complemented by comprehensive support programmes for both medical professionals and patients. We launched our first Bone Health product in 2014 having identified an unmet need for prescribers and patients to have access to licenced medicines within the vitamin D therapeutic area.
We are a Medical Technologies Solutions Provider offering software and services that help identify patients requiring medically necessary care.
Through our ASPIRE case finding service, we optimize Fracture Liaison Services (FLS) through opportunistic identification of vertebral fracture patients with osteoporosis. Anonymized patient images, acquired to investigate other conditions, are securely transferred to Optasia for rapid machine learning analysis and over read by a radiologist. Identified fracture patients are reported back to the FLS for investigation and management.
We also provide solutions to the clinical trials and research sectors for accurate and precise anatomical measurements related to disease state.
Amgen unlocks the potential of biology for patients suffering from serious illnesses - developing and delivering innovative medicines using advanced human genetics to unravel the complexities of disease. A biotechnology pioneer since 1980, Amgen is today one of the world's leading independent biotechnology companies. For more information, visit www.amgen.co.uk
UCB is a Global biopharmaceutical company focused on discovering and developing innovative medicines and forming working partnerships with the scientific and medical community to create solutions to transform the lives of patients in the UK. UCB has built a strong presence across neurology and immunology with several in-licence products and a strong pipeline. Today, we are building our pipeline in our existing therapy areas of focus and expanding our research into the area of bone health where we hope to bring novel therapies to reduce the burden of the half a million fragility fractures caused by osteoporosis in the UK every year.
Your generosity changes lives
By donating, you’ll be supporting vital services like our Helpline, website and free publications.